Public comment sought on EHR cert. final rule test procedures

Laura Pedulli | | Health Exec | EMR/EHR

The Office of the National Coordinator for Health IT (ONC) is soliciting public comment on draft test procedures associated with the 2014 Edition Release 2 Certification Criteria final rule.

“ONC values stakeholder feedback and invites you to provide input through this public comment process which begins today and runs through Nov. 7,” according to a notice.

Test procedures can be accessed here for public review and comment. All public comments are accessible on the ONC Public comment JIRA project.

The agency expects to finalize and post test procedures in December this year.


 

Laura Pedulli

Related Content

Christmas ransomware exposed over 300K patient records to dark web
Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.